OrderlyMeds launches weight loss calculator using clinical trial data to help individuals estimate GLP-1 medication outcomes, providing personalized metrics and evidence-based expectations for those considering treatment.
-- OrderlyMeds has launched a weight loss calculator designed to help individuals estimate potential outcomes when using GLP-1 medications, drawing on clinical trial data from established treatments. The tool references results from Wegovy (semaglutide) and Zepbound (tirzepatide) trials, which demonstrated average weight loss of 15% and 20%, respectively, over 68 to 72 weeks when combined with diet and exercise modifications. By grounding estimates in peer-reviewed research, the calculator addresses a gap for those considering GLP-1 treatment who need transparent, evidence-based expectations before committing to therapy.
More information is available at https://orderlymeds.com/weight-loss-calculator/
Individuals considering GLP-1 medications often face uncertainty about realistic weight loss potential and lack personalized, data-driven guidance tailored to their circumstances. While clinical trial data provides average outcomes across large populations, prospective patients need a method to estimate their own results based on individual health profiles. The calculator bridges this divide between aggregate research findings and personal decision-making, offering a practical entry point for informed conversations with healthcare providers.
The calculator delivers specific metrics beyond generic weight loss projections. Users receive estimated Body Mass Index changes, Total Daily Energy Expenditure, and daily protein targets customized to user-provided data. These personalized recommendations reflect individual health profiles and goals rather than one-size-fits-all estimates, helping patients set realistic expectations before beginning treatment. The tool represents one component of a structured approach to weight management that combines clinical evidence, personalized metrics, and expert-led support designed to help patients succeed beyond initial weight loss.
OrderlyMeds integrates the new calculator within a broader treatment framework that includes physician oversight, ongoing support, and transparent, all-inclusive pricing. The company offers both branded GLP-1 medications—Wegovy and Zepbound—and compounded alternatives available as semaglutide injections or oral tablets, and tirzepatide injections. This range of options allows medical providers to tailor prescriptions to patient needs and preferences, while the calculator serves as an initial assessment tool within a care program.
GLP1 Match, an independent review platform, awarded OrderlyMeds a score of 88 out of 100, highlighting competitive pricing relative to other providers and availability across all 50 states. OrderlyMeds provides medical provider consultations completed within 48 hours in most cases, along with educational webinars led by experts, including board-certified bariatric surgeon Dr. William Yi and registered dietitian Kristin Kirkpatrick.
Those ready to consider GLP-1 treatment options can access the calculator and eligibility screening through the OrderlyMeds platform, where medical professionals evaluate individual suitability for therapy.
For more details, visit https://orderlymeds.com/
Contact Info:
Name: Annie Dawson
Email: Send Email
Organization: OrderlyMeds
Address: 235 Ponce De Leon Pl Suite M347, Decatur, Georgia 30030, United States
Website: https://orderlymeds.com/
Source: PressCable
Release ID: 89183897
Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.
